mRNA Vaccine Technology Downgraded

The United States government recently announced changes to existing and future investment in messenger ribonucleic acid (mRNA) vaccine technology, which was discovered in the early 1960s.

On August 5, 2025, the U.S. Department of Health and Human Services (HHS) stated that a coordinated wind-down of its mRNA vaccine development activities under the U.S. Biomedical Advanced Research and Development Authority (BARDA) had begun, including the cancellation and de-scoping of various contracts and solicitations.

The HHS decision follows a comprehensive review of mRNA-related investments initiated during the recent public health emergency.

"We reviewed the science, listened to the experts, and acted," said HHS Secretary Robert F. Kennedy, Jr., in a press release. 

"BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu."

"We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate."

While some final-stage contracts will be allowed to run their course to preserve prior taxpayer investment, no new mRNA-based projects will be initiated.

This announcement does not impact other uses of mRNA technology within BARDA.

"Let me be absolutely clear: HHS supports safe, effective vaccines for every American who wants them. That's why we're moving beyond the limitations of mRNA and investing in better solutions," added Secretary Kennedy.

In late May 2025, the Centers for Disease Control and Prevention released the 2025 immunization schedules for children, adolescents and adults.